Literature DB >> 29226065

Challenges and Opportunities in Studying the Epidemiology of Ovarian Cancer Subtypes.

Jennifer Anne Doherty1, Lauren Cole Peres2, Chen Wang3, Gregory P Way4, Casey S Greene4, Joellen M Schildkraut2.   

Abstract

PURPOSE OF REVIEW: Only recently has it become clear that epithelial ovarian cancer (EOC) is comprised of such distinct histotypes--with different cells of origin, morphology, molecular features, epidemiologic factors, clinical features, and survival patterns-that they can be thought of as different diseases sharing an anatomical location. Herein, we review opportunities and challenges in studying EOC heterogeneity. RECENT
FINDINGS: The 2014 World Health Organization diagnostic guidelines incorporate accumulated evidence that high- and low-grade serous tumors have different underlying pathogenesis, and that, on the basis of shared molecular features, most high grade tumors, including some previously classified as endometrioid, are now considered to be high-grade serous. At the same time, several studies have reported that high-grade serous EOC, which is the most common histotype, is itself made up of reproducible subtypes discernable by gene expression patterns.
SUMMARY: These major advances in understanding set the stage for a new era of research on EOC risk and clinical outcomes with the potential to reduce morbidity and mortality. We highlight the need for multidisciplinary studies with pathology review using the current guidelines, further molecular characterization of the histotypes and subtypes, inclusion of women of diverse racial/ethnic and socioeconomic backgrounds, and updated epidemiologic and clinical data relevant to current generations of women at risk of EOC.

Entities:  

Keywords:  Epithelial ovarian cancer; gene expression subtype; histotype; pathology; survival

Year:  2017        PMID: 29226065      PMCID: PMC5718213          DOI: 10.1007/s40471-017-0115-y

Source DB:  PubMed          Journal:  Curr Epidemiol Rep


  101 in total

1.  Breast cancer molecular subtypes respond differently to preoperative chemotherapy.

Authors:  Roman Rouzier; Charles M Perou; W Fraser Symmans; Nuhad Ibrahim; Massimo Cristofanilli; Keith Anderson; Kenneth R Hess; James Stec; Mark Ayers; Peter Wagner; Paolo Morandi; Chang Fan; Islam Rabiul; Jeffrey S Ross; Gabriel N Hortobagyi; Lajos Pusztai
Journal:  Clin Cancer Res       Date:  2005-08-15       Impact factor: 12.531

Review 2.  Treatment issues in clear cell carcinoma of the ovary: a different entity?

Authors:  Dimitrios Pectasides; Eirini Pectasides; Amanda Psyrri; Theofanis Economopoulos
Journal:  Oncologist       Date:  2006 Nov-Dec

Review 3.  The distal fallopian tube: a new model for pelvic serous carcinogenesis.

Authors:  Christopher P Crum; Ronny Drapkin; Alexander Miron; Tan A Ince; Michael Muto; David W Kindelberger; Yonghee Lee
Journal:  Curr Opin Obstet Gynecol       Date:  2007-02       Impact factor: 1.927

4.  Differences in risk factors for breast cancer molecular subtypes in a population-based study.

Authors:  Xiaohong R Yang; Mark E Sherman; David L Rimm; Jolanta Lissowska; Louise A Brinton; Beata Peplonska; Stephen M Hewitt; William F Anderson; Neonila Szeszenia-Dabrowska; Alicja Bardin-Mikolajczak; Witold Zatonski; Richard Cartun; Daniza Mandich; Grzegorz Rymkiewicz; Marcin Ligaj; Stanislaw Lukaszek; Radzisaw Kordek; Montserrat García-Closas
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-03       Impact factor: 4.254

Review 5.  Molecular classification and molecular forecasting of breast cancer: ready for clinical application?

Authors:  James D Brenton; Lisa A Carey; Ahmed Ashour Ahmed; Carlos Caldas
Journal:  J Clin Oncol       Date:  2005-09-06       Impact factor: 44.544

6.  Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer.

Authors:  J M Piek; P J van Diest; R P Zweemer; J W Jansen; R J Poort-Keesom; F H Menko; J J Gille; A P Jongsma; G Pals; P Kenemans; R H Verheijen
Journal:  J Pathol       Date:  2001-11       Impact factor: 7.996

7.  Histologic types of epithelial ovarian cancer: have they different risk factors?

Authors:  Allison W Kurian; Raymond R Balise; Valerie McGuire; Alice S Whittemore
Journal:  Gynecol Oncol       Date:  2005-02       Impact factor: 5.482

8.  The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.

Authors:  Lisa A Carey; E Claire Dees; Lynda Sawyer; Lisa Gatti; Dominic T Moore; Frances Collichio; David W Ollila; Carolyn I Sartor; Mark L Graham; Charles M Perou
Journal:  Clin Cancer Res       Date:  2007-04-15       Impact factor: 12.531

9.  Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.

Authors:  William E Winter; G Larry Maxwell; Chunqiao Tian; Jay W Carlson; Robert F Ozols; Peter G Rose; Maurie Markman; Deborah K Armstrong; Franco Muggia; William P McGuire
Journal:  J Clin Oncol       Date:  2007-08-20       Impact factor: 44.544

10.  Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment.

Authors:  Viviane Hess; Roger A'Hern; Nazar Nasiri; D Michael King; Peter R Blake; Desmond P J Barton; John H Shepherd; T Ind; J Bridges; K Harrington; Stanley B Kaye; Martin E Gore
Journal:  J Clin Oncol       Date:  2004-03-15       Impact factor: 44.544

View more
  21 in total

1.  Ovarian Cancer in Women of African Ancestry (OCWAA) consortium: a resource of harmonized data from eight epidemiologic studies of African American and white women.

Authors:  Joellen M Schildkraut; Lauren C Peres; Traci N Bethea; Fabian Camacho; Deanna Chyn; Emily K Cloyd; Elisa V Bandera; Alicia Beeghly-Fadiel; Loren Lipworth; Charlotte E Joslin; Faith G Davis; Patricia G Moorman; Evan Myers; Heather M Ochs-Balcom; Veronica Wendy Setiawan; Malcolm C Pike; Anna H Wu; Lynn Rosenberg
Journal:  Cancer Causes Control       Date:  2019-06-24       Impact factor: 2.506

2.  Invited Commentary: Relationship Between Ovulation and Markers of Systemic Inflammation Versus Markers of Localized Inflammation.

Authors:  Joellen M Schildkraut
Journal:  Am J Epidemiol       Date:  2020-07-01       Impact factor: 4.897

3.  Leptin Receptor Antagonists' Action on HDAC Expression Eliminating the Negative Effects of Leptin in Ovarian Cancer.

Authors:  Elżbieta Fiedor; Karolina Zajda; Ewa L Gregoraszczuk
Journal:  Cancer Genomics Proteomics       Date:  2018 Jul-Aug       Impact factor: 4.069

4.  Histotype classification of ovarian carcinoma: A comparison of approaches.

Authors:  Lauren C Peres; Kara L Cushing-Haugen; Michael Anglesio; Kristine Wicklund; Rex Bentley; Andrew Berchuck; Linda E Kelemen; Tayyebeh M Nazeran; C Blake Gilks; Holly R Harris; David G Huntsman; Joellen M Schildkraut; Mary Anne Rossing; Martin Köbel; Jennifer A Doherty
Journal:  Gynecol Oncol       Date:  2018-08-16       Impact factor: 5.482

5.  LncRNA CRNDE promotes cell proliferation, migration and invasion of ovarian cancer via miR-423-5p/FSCN1 axis.

Authors:  Qiong Wang; Ling-Xiong Wang; Chun-Yan Zhang; Nan Bai; Chen Feng; Zhuo-Mei Zhang; Liang Wang; Zhen-Zhen Gao
Journal:  Mol Cell Biochem       Date:  2022-02-15       Impact factor: 3.396

Review 6.  Current Gaps in Ovarian Cancer Epidemiology: The Need for New Population-Based Research.

Authors:  Jennifer A Doherty; Allan Jensen; Linda E Kelemen; Celeste L Pearce; Elizabeth Poole; Joellen M Schildkraut; Kathryn L Terry; Shelley S Tworoger; Penelope M Webb; Nicolas Wentzensen
Journal:  J Natl Cancer Inst       Date:  2017-10-01       Impact factor: 13.506

Review 7.  WNT4 Balances Development vs Disease in Gynecologic Tissues and Women's Health.

Authors:  Lauren M Pitzer; Marisa R Moroney; Natalie J Nokoff; Matthew J Sikora
Journal:  Endocrinology       Date:  2021-07-01       Impact factor: 4.736

8.  Spatial cytotoxic and memory T cells in tumor predict superior survival outcomes in patients with high-grade serous ovarian cancer.

Authors:  Guodong Zhang; Qing Xu; Xiangyun Zhang; Moran Yang; Yiying Wang; Mengdi He; Jiaqi Lu; Haiou Liu
Journal:  Cancer Med       Date:  2021-05-05       Impact factor: 4.452

9.  A Liquid-Liquid Phase Separation-Related Gene Signature as Prognostic Biomarker for Epithelial Ovarian Cancer.

Authors:  Yan Qiu; Min Pan; Xuemei Chen
Journal:  Front Oncol       Date:  2021-06-08       Impact factor: 6.244

Review 10.  New Predictive Biomarkers for Ovarian Cancer.

Authors:  Ghofraan Abdulsalam Atallah; Nor Haslinda Abd Aziz; Chew Kah Teik; Mohamad Nasir Shafiee; Nirmala Chandralega Kampan
Journal:  Diagnostics (Basel)       Date:  2021-03-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.